| Company | Location | Amount | Technology Focus (Date) |
| (C$, M)* | |||
| Bioniche Inc. | London, Ontario | 2.4 | Therapeutics for bladder cancer |
| (ME, TSE:BNC) | and interstitial cystitis (8/98) | ||
| CliniChem Development Inc. | Montreal | 150 | Antiviral and anticancer |
| (ME, TSE:BCC.A; NASDAQ:CCHE) | therapeutics and vaccines (6/98) | ||
| Haemacure Corp. | Montreal | 6.8 | Bioadhesives (8/98) |
| (ME, TSE:HAE) | |||
| Hemosol Inc. | Toronto | 7.3 | Blood substitutes (7/98) |
| (TSE:HML) | |||
| Inflazyme Pharmaceuticals Ltd. | Vancouver, | 6 | Therapeutics that act by regulating gene |
| (VSE:IZP; OTC Bulletin Board:IZYPF) | British Columbia | expression; inflammatory diseases (6/98) | |
| Nymox Corp. | Montreal | 4.1 | Alzheimer's disease diagnostics |
| (ME:NMX; NASDAQ:NYMXF) | (4/98) | ||
| QLT PhotoTherapeutics Inc. | Vancouver, | 23 | Photodynamic therapy (7/98) |
| (TSE:QLT; NASDAQ:QLTIF) | British Columbia | ||
| StressGen Biotechnologies Corp. | Victoria, | 23.2 | Immunotherapy products to treat cancer |
| (TSE:SSB) | British Columbia | and prevent infectious diseases (6/98) | |
| Theratechnologies Inc. (ME:TH) | Montreal | 11.25 | Therapeutics for AIDS, cardiovascular |
| disease, prostate cancer; photodynamic | |||
| treatment of bone marrow cancers (5/98) | |||
| Tm Bioscience Corp. (VSE:TMC) | Toronto | 14.8 | Genomics; DNA products (6/98) |
| TOTAL: | C$248.85M | ||
| NOTES: | |||
| * Amounts are quoted in Canadian dollars. The exchange rate on 9/10/98 was C$1.52/US$1. | |||
| ME = Montreal Exchange; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange | |||
